amiodarone has been researched along with Cryptococcosis in 2 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Cryptococcosis: Fungal infection caused by genus CRYPTOCOCCUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone treatment influenced some virulence factors, interrupting the calcium-calcineurin signaling pathway." | 1.62 | New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect. ( Barcellos, VA; Frank, LA; Garcia, AWA; Guterres, SS; Kinskovski, UP; Kmetzsch, L; Marques, BM; Motta, H; Oliveira, NK; Pohlmann, AR; Reuwsaat, JCV; Schrank, A; Squizani, ED; Staats, CC; Vainstein, MH, 2021) |
| " A significant portion of the drugs are orally bioavailable and cross the blood-brain barrier, features key to the development of a widely applicable anticryptococcal agent." | 1.39 | A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. ( Baxter, BK; Butts, A; Chabrier-Rosello, Y; DiDone, L; Koselny, K; Krysan, DJ; Wellington, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oliveira, NK | 1 |
| Frank, LA | 1 |
| Squizani, ED | 1 |
| Reuwsaat, JCV | 1 |
| Marques, BM | 1 |
| Motta, H | 1 |
| Garcia, AWA | 1 |
| Kinskovski, UP | 1 |
| Barcellos, VA | 1 |
| Schrank, A | 1 |
| Pohlmann, AR | 1 |
| Staats, CC | 1 |
| Guterres, SS | 1 |
| Vainstein, MH | 1 |
| Kmetzsch, L | 1 |
| Butts, A | 1 |
| DiDone, L | 1 |
| Koselny, K | 1 |
| Baxter, BK | 1 |
| Chabrier-Rosello, Y | 1 |
| Wellington, M | 1 |
| Krysan, DJ | 1 |
2 other studies available for amiodarone and Cryptococcosis
| Article | Year |
|---|---|
New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect.
Topics: Amiodarone; Animals; Antifungal Agents; Cryptococcosis; Fluconazole; Lipids; Mice; Microbial Sensiti | 2021 |
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
Topics: Adenylate Kinase; Amiodarone; Animals; Antifungal Agents; Calmodulin; Cells, Cultured; Cryptococcosi | 2013 |